MRNA Stock Forecast: Moderna, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$195
−2.12% on the day

The 23 Wall Street analysts covering Moderna, Inc. hold a median 12-month price target of $145 — -25.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 84 of 100 as at 21 Nov 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$80.7B
Ticker Nerd rank
84/ 100
Median analyst target
$145
Analysts covering
23
Revenue$143.0M+4.4% y/y
Operating income−$815.0M
Net income−$782.0M
Free cash flow−$563.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.7%
1M
−19.4%
YTD
+561.6%
1Y
+772.6%
From 52W high
−27.5%
From 52W low
+772.6%
$22
$269
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Moderna, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
84/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Value
95
Growth
85
Revisions
84
Quality
77
Accruals
57
Volatility
55
Issuance
16

Momentum (98): The shares have been drifting up relative to others.

Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MRNA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MRNA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150$200$250$300$350Jan 26Apr 26Jul 26Oct 26MRNAHigh $305Median $145Low $45

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says23 analysts
4
Buy
16
Hold
3
Sell
$45
Low
$145
Median
$305
High

The green dot is the last close — the median target sits −25.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 16 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
17 Nov 2026JP MorganMaintainsUnderweight$77 → $102
17 Nov 2026Morgan StanleyMaintainsEqual-Weight$95 → $200
9 Nov 2026Goldman SachsMaintainsNeutral$137 → $195
9 Nov 2026Piper SandlerReiteratesOverweight$230 → $305
27 Oct 2026William BlairDowngradeMarket Perform—
26 Oct 2026Piper SandlerReiteratesOverweight$167 → $230
21 Oct 2026TD CowenMaintainsHold$40 → $90
15 Oct 2026Goldman SachsMaintainsNeutral$120 → $137
7 Oct 2026Morgan StanleyMaintainsEqual-Weight$89 → $95
30 Sept 2026CitigroupDowngradeSell$60 → $80
3 Sept 2026Rothschild & CoDowngradeSell$40 → $81
28 Aug 2026Argus ResearchUpgradeBuy$180
25 Aug 2026Wolfe ResearchUpgradePeer Perform—
24 Aug 2026BarclaysMaintainsEqual-Weight$48 → $125
21 Aug 2026JP MorganMaintainsUnderweight$40 → $77
20 Aug 2026Goldman SachsMaintainsNeutral$67 → $120
20 Aug 2026Morgan StanleyMaintainsEqual-Weight$39 → $89
20 Aug 2026UBSMaintainsNeutral$50 → $150
19 Aug 2026William BlairUpgradeOutperform—
3 Aug 2026CitigroupMaintainsNeutral$41 → $60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MRNA.

Market Radar

This page is one stock. Monday covers all of them.

MRNA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MRNA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Moderna, Inc. returned +772.6% against +6.9% for the S&P 500, dividends included.

MRNA vs S&P 500, last 12 monthsTotal return, rebased to 100
02004006008001,0001,200Jan 26Apr 26Jul 26Oct 26MRNAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MRNA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
6
Analysts cutting
2
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
32.9×

Cheaper than 6% of US stocks

Price / book
12.1×

Cheaper than 6% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
35.0%

Higher than 42% of US stocks

Operating margin
−80.8%

Higher than 15% of US stocks

Net margin
—
Returns & dividend
Return on equity
−34.5%

Higher than 26% of US stocks

Return on assets
−10.0%

Higher than 26% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Moderna, Inc. has a market value of $80.7B and an enterprise value of $79.7B.

  • Revenue in the twelve months to 30 June 2026: $2.2B. The latest quarter grew 4.4% year on year.

  • Net income over the same four quarters: −$3.2B, a −142.6% net margin.

  • Diluted earnings per share, trailing twelve months: −$7.99.

  • Free cash flow in the twelve months to 30 June 2026: −$1.2B.

  • Shares outstanding: 399.0M.

  • Moderna, Inc. employs 4,700 people — $470K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

MRNA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MRNAModerna, Inc.$80.7B84
REGNRegeneron Pharmaceuticals, Inc.$96.7B97
VRTXVertex Pharmaceuticals, Inc.$130.7B61
RPRXRoyalty Pharma Plc$39.4B97
RVMDRevolution Medicines, Inc.$33.6B56
INSMInsmed, Inc.$30.9B76
ROIVRoivant Sciences Ltd.$27.7B83

Take a look at MRNA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Moderna, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about MRNA

What is the MRNA stock price forecast for 2026-2027?

The 23 Wall Street analysts covering Moderna, Inc. have a median 12-month price target of $145, with estimates ranging from $45 to $305. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MRNA stock a buy right now?

Of the 23 analysts covering Moderna, Inc., 4 rate it a Buy, 16 a Hold and 3 a Sell. Ticker Nerd's systematic factor model ranks Moderna, Inc. 84 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MRNA?

As at 21 Nov 2026, Moderna, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will MRNA stock go up?

No one can know that. What the data says: the median 12-month target from 23 analysts implies -25.7% from the last close, and Ticker Nerd's factor model ranks Moderna, Inc. 84 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MRNA stock forecast for 2030?

No analyst covering Moderna, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MRNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $45 to $305 over the next 12 months.

How has MRNA stock performed over the past year?

Moderna, Inc. returned +772.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Moderna, Inc. do?

Moderna Inc. is a biotechnology company focused on developing medicines and vaccines based on messenger RNA (mRNA) technology. Its commercial portfolio includes respiratory and infectious disease vaccines, while its broader pipeline spans oncology, rare diseases, autoimmune conditions, and other therapeutic areas.

Company

About Moderna, Inc.

Moderna Inc. is a biotechnology company focused on developing medicines and vaccines based on messenger RNA (mRNA) technology. Its commercial portfolio includes respiratory and infectious disease vaccines, while its broader pipeline spans oncology, rare diseases, autoimmune conditions, and other therapeutic areas. Moderna uses its mRNA platform to design products that instruct cells to produce proteins or immune responses relevant to prevention and treatment. The company also works with manufacturing and commercialization capabilities to support product development and distribution across major healthcare markets. Headquartered in Cambridge, Massachusetts, Moderna plays a significant role in the biopharmaceutical industry by advancing a new class of medicines across vaccines and therapeutics.

CEO Mr. Stéphane Bancel M.B.A. · 4,700 employees · United States · https://www.modernatx.com